Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting
Current Oncology · 2024
DOI: 10.3390/curroncol31110484 ↗Kurz gefasst
Leitlinie in der Zeitschrift Current Oncology, 2024. Verfasst von Mita Manna und 19 weiteren Autor:innen. Beteiligte Einrichtung: Saskatchewan Cancer Agency, Regina, SK S4W 0G3, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Breast Cancer Canada.
Abstract (Originalsprache)
Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive subtype of breast cancer associated with a poor prognosis when sub-optimally treated. Recent advances include new and effective targeted therapies that have significantly improved outcomes for patients. Despite these advances, there are significant gaps across Canada, underscoring the need for evidence-based consensus guidance to inform treatment decisions. Addressing these gaps is crucial to ensuring that effective therapies are integrated into clinical practice, so as to improve the lives of patients affected by this aggressive form of breast cancer. The Research Excellence, Active Leadership (REAL) Canadian Breast Cancer Alliance is a standing nucleus committee of clinical-academic oncologists across Canada and Breast Cancer Canada, a patient organization. The mandate of this group is to provide evidence-based guidance on best practices in the management of patients with breast cancer. These consensus recommendations were developed using a modified Delphi process with up to three rounds of anonymous voting. Consensus was defined a priori as ≥75% of voters agreeing with the recommendation as written. There are 9 recommendations in the early setting; 7 recommendations in the metastatic setting; and 10 recommendations for patients with brain metastases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Saskatchewan Cancer Agency, Regina, SK S4W 0G3, Canada.
- BC Cancer-Vancouver, Vancouver, BC V5Z 4E6, Canada.
- Jewish General Hospital, Montreal, QC H3T 1E2, Canada.
- Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada.
- Tom Baker Cancer Centre, Calgary, AB T2N 4N2, Canada.
- Sunnybrook Health Sciences, Toronto, ON M4N 3M5, Canada.
ORCID-Profile: Mita Manna, Karen A Gelmon, Christine Brezden-Masley, Ipshita Prakash, Sandeep Sehdev, Nathaniel Bouganim, Muriel Brackstone, David W Cescon, Jan-Willem Henning
Förderung
- Breast Cancer Canada
Zitieren
APA
Manna, M., Gelmon, K. A., Boileau, J. F., Brezden-Masley, C., Cao, J. Q., Jerzak, K. J., Prakash, I., Sehdev, S., Simmons, C., Bouganim, N., Brackstone, M., Cescon, D. W., Chia, S., Dayes, I. S., Edwards, S., Hilton, J., Joy, A. A., Laing, K., Webster, M., & Henning, J. W. (2024). Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting. Current Oncology. https://doi.org/10.3390/curroncol31110484
Vancouver
Manna M, Gelmon KA, Boileau JF, Brezden-Masley C, Cao JQ, Jerzak KJ, et al. Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting. Current Oncology. 2024. doi:10.3390/curroncol31110484
BibTeX
@article{Manna2024,
author = {Manna, Mita and Gelmon, Karen A and Boileau, Jean-François and Brezden-Masley, Christine and Cao, Jeffrey Q and Jerzak, Katarzyna J and Prakash, Ipshita and Sehdev, Sandeep and Simmons, Christine and Bouganim, Nathaniel and Brackstone, Muriel and Cescon, David W and Chia, Stephen and Dayes, Ian S and Edwards, Scott and Hilton, John and Joy, Anil Abraham and Laing, Kara and Webster, Marc and Henning, Jan-Willem},
title = {Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting},
journal = {Current Oncology},
year = {2024},
doi = {10.3390/curroncol31110484}
}
EUVIMED